Medical News

RSS

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

Health Discovery Corporation, a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, has entered into an exclusive worldwide licensing agreement with NeoGenomics, Inc. for laboratory developed tests in the Field of hematopoietic and solid tumor cancers excluding breast cancer, which was previously licensed to Quest Diagnostics and Smart Personalized Medicine and excluding cancer of the retina which was previously committed to Retinalyze, LLC.

9 Jan 2012

Cameron Health's PMA application for S-ICD System submitted to FDA

Cameron Health, Inc. announced today that it has submitted the Premarket Approval application to the Food and Drug Administration for the S-ICD System, the world's only completely subcutaneous implantable defibrillator.

9 Jan 2012

Idenix Pharmaceuticals makes progress with its HCV development pipeline

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the advancement of its hepatitis C virus development pipeline.

9 Jan 2012

DATATRAK International releases its new product, uCTMS

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the release of its new product, uCTMS.

9 Jan 2012

Sangamo BioSciences starts Phase 2 clinical studies to develop functional cure for HIV/AIDS

Sangamo BioSciences, Inc. announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS.

9 Jan 2012

Progress report on commercialization of BENLYSTA to be announced at JPMorgan Healthcare Conference

Human Genome Sciences, Inc. will today announce its priority goals for 2012 and report on progress with the commercialization of BENLYSTA (belimumab), the first approved drug for systemic lupus in 56 years, during a presentation this afternoon by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 30th Annual JPMorgan Healthcare Conference in San Francisco.

9 Jan 2012

Merck selects Idera Pharmaceuticals' TLR agonists for evaluation, use as vaccine adjuvant candidates

Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.

9 Jan 2012

First Edition: January 9, 2012

Today's early morning highlights from the major news organizations, including reports about the government's health law defense and the weekend's GOP presidential primary debates.

9 Jan 2012

Neurotechnology announces new line of embedded biometric technologies

Neurotechnology, a provider of high-precision biometric identification technologies, today announced their new line of embedded biometric technologies, including VeriFinger Embedded SDK for fingerprint biometrics, VeriLook Embedded SDK for face biometrics and MegaMatcher Embedded SDK for multi-biometric systems using face and fingerprints in combination.

9 Jan 2012

Pacira provides updated timing for commercial launch of EXPAREL

Pacira Pharmaceuticals, Inc. today provided updated timing for its commercial launch of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid analgesic that was approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.

9 Jan 2012

Presidio completes PPI-668 Phase 1a study on hepatitis C

Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a dose-ranging assessment of PPI-668, a potent, pan-genotypic second-generation hepatitis C virus (HCV) NS5A inhibitor, in healthy volunteers and subsequent advancement to a Phase 1b assessment of the dose-related efficacy in hepatitis C patients.

9 Jan 2012

Clear link between marijuana use in young males and cyclic vomiting syndrome

Researchers have found clear associations between marijuana use in young males and cyclic vomiting syndrome (CVS), where patients experience episodes of vomiting separated by symptom free intervals.

9 Jan 2012

TRON uses Ingenuity Variant Analysis to identify cancer driver variants

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced that TRON has used Ingenuity Variant Analysis to identify cancer driver variants that inform the development of an experimental individualized RNA-based therapeutic.

9 Jan 2012

Houston bursts with customers for n3D's Bio-Assembler system

Houston, Texas, the home base of Rainbow Coral Corp.'s biosciences division, is bursting with potential customers for n3D's Bio-Assembler system. Just last month, the largest stem cell lab and bank in North America opened in Sugar Land, the city's fastest-growing suburb.

9 Jan 2012

CCPR completes new specialty behavioral health provider network

Comprehensive Care Corporation, which provides behavioral health, substance abuse and at-risk psychotropic pharmacy management services for managed care companies throughout the U.S. and Puerto Rico, is pleased to announce that CompCare de Puerto Rico (CCPR) has completed its build out of a fully contracted and credentialed specialty behavioral health provider network to better serve its clients and insured Medicare and dual-eligible members across the Island of Puerto Rico.

9 Jan 2012

Neutra closes formulation phase for new all-natural weight-loss supplement

Neutra Corp., an emerging nutraceuticals provider, announced today that the company is close to finalizing the formula for its new all-natural weight-loss supplement.

9 Jan 2012

BioCells opens new franchise headquartered in Campinas, Brazil

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that Biocordcell Argentina S.A. is opening a new franchise headquartered in Campinas, Brazil, a city of more than one million in the state of Sao Paulo.

9 Jan 2012

Genentech, Xenon partner to discover and develop novel pain relieving medicines

Xenon today announced a strategic alliance with Genentech, a member of the Roche Group, to discover and develop compounds and companion diagnostics for the potential treatment of pain.

9 Jan 2012

Pfizer, SFJ to conduct axitinib Phase 3 trial in renal cell carcinoma

SFJ Pharma Ltd. II announced today that it has entered into a collaborative development agreement with Pfizer Inc. to conduct a Phase 3 clinical trial in Asia of Pfizer's investigational agent axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy.

9 Jan 2012

JDRF, KalVista collaborate to focus on novel approach for diabetic macular edema

KalVista Pharmaceuticals and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease.

9 Jan 2012